What AGB-Pharma does

AGB-Pharma AB is a privately held, family-owned Swedish pharmaceutical company founded in 2020 in Lund, Sweden, focused exclusively on sleep health. It develops, manufactures and markets registered melatonin receptor agonist tablet medicines under the brands Melatonin AGB® (1-5 mg) and Pinealin® (0.5-5 mg). Both products are indicated for short-term treatment of jet lag in adults and for insomnia in children and adolescents aged 6-17 with ADHD where sleep hygiene measures have been insufficient; Pinealin offers a lower 0.5 mg dose and is explicitly not interchangeable at the pharmacy, supporting individualized titration.

The company's technical and operational backbone is EU-GMP certified manufacturing in Scandinavia with locally held active-substance and excipient inventory and scalable production, which AGB-Pharma states has kept its products never out of stock in Sweden. Marketed claims are anchored in clinical evidence, including a >30% reduction in sleep onset time versus 12.8% for placebo (p=0.001) in children with ADHD and chronic sleep-onset insomnia, and replicated jet-lag symptom reduction in 8 of 10 trials. Its leadership team carries multi-decade tenures at major pharmaceutical firms including AstraZeneca, Pharmacia, Pfizer Consumer Healthcare, Ferring Läkemedel, Bioglan and Gambro/Baxter, supplying regulatory, QA, PV and operations depth.

AGB-Pharma operates a sales-led, prescription-only (Rx) go-to-market that routes through pharmacies with reimbursement or subsidy in approved indications in Sweden and Norway. The company is currently commercialized in Sweden, Norway, Denmark, the UK and Germany, with France referenced in its market scope. Pricing is unit-based and varies by market and strength; Pinealin's 0.5-5 mg range is priced at the lower end among comparable melatonin products in Sweden (2.81 SEK/tablet), while Melatonin AGB lists at 5.79 SEK/tablet, with Norway pack prices of 184.50-625.60 NOK. The company is EFPIA Disclosure Code compliant and member of the Swedish pharmaceutical industry association (Forska!Sverige/Läkemedelsföretagen).

Name

AGB-Pharma

Legal name

AGB-Pharma AB

Website

https://agb-pharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

AGB-Pharma AB is a Swedish pharmaceutical company that develops and markets melatonin receptor agonist tablets (Melatonin AGB, Pinealin) for pediatric ADHD insomnia and adult jet lag, sold via pharmacies across Sweden, Norway, Denmark, the UK and Germany.

Ownership category

akta.pro rank

Product category

Sleep Disorder Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sleep, Stress & Mood Support (HLAIADAG)

Keywords

• Melatonin pharmaceuticals
• Sleep disorder treatments
• Pediatric insomnia medication
• ADHD sleep solutions
• Prescription melatonin tablets

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Others, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: AGB-Pharma generates revenue through the manufacture and sale of melatonin-based prescription pharmaceuticals. Products include Melatonin AGB (1-5 mg tablets) and Pinealin (0.5-5 mg tablets) distributed through pharmacies in Sweden, Norway, Denmark, UK, and Germany. Revenue is derived from prescription drug sales with subsidies/reimbursements for approved indications.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

AGB-Pharma AB develops, manufactures, and markets melatonin-based prescription pharmaceuticals for sleep disorders. Its two core products — Melatonin AGB® (1-5 mg tablets, registered since December 2019) and Pinealin® (0.5-5 mg tablets) — are indicated for insomnia in children and adolescents aged 6-17 years with ADHD where sleep hygiene measures have been insufficient, and for short-term treatment of jet lag in adults. Products are distributed via prescription pharmacies across Sweden, Norway, Denmark, the UK, and Germany, with reimbursement/subsidy granted for approved indications.

Product overview

AGB-Pharma is a Swedish pharmaceutical company focused on sleep health, offering melatonin-based medications for sleep disorders. The company has two main products: Melatonin AGB® (1-5mg tablets) and Pinealin® (0.5-5mg tablets). Both products are indicated for short-term treatment of jet lag in adults and insomnia in children and adolescents 6-17 years with ADHD where sleep hygiene measures have been insufficient. Melatonin AGB is registered since December 2019 and is substitutable at pharmacies, while Pinealin is not interchangeable at pharmacies.

Differentiator

Problem solved

Functional benefit

Brands

• Melatonin AGB: Melatonin receptor agonist in tablet form available in strengths 1-5 mg for treatment of insomnia in children and adolescents with ADHD and short-term treatment of jet lag in adults.
• Pinealin

Products and services

• Melatonin AGB® Melatonin receptor agonist in tablet form for short-term treatment of jet lag in adults and insomnia in children and adolescents 6-17 years with ADHD where sleep hygiene measures have been insufficient. Available in 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg tablets in packages of 30 and 100 tablets. Sold as a prescription pharmaceutical through pharmacies across Sweden, Norway, Denmark, UK, and Germany.
• Pinealin® Melatonin medication in tablet form for short-term treatment of jet lag in adults and insomnia in children and adolescents 6-17 years with ADHD where sleep hygiene measures have been insufficient. Available in 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg tablets. Not interchangeable at pharmacies. Sold as a prescription pharmaceutical through pharmacies across Sweden, Norway, Denmark, UK, and Germany, with reimbursed/subsidized status in Sweden for ADHD-related insomnia in children/youth 6-17 years.

Quantifiable outcome

• Sleep onset time improved by >30% compared to 12.8% for placebo (p=0.001) in children with ADHD and chronic sleep-onset insomnia
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Sandoz (Novartis): Sandoz is one of the largest generic Rx manufacturers globally and markets generic melatonin in multiple European markets. As a broad incumbent with scale that AGB-Pharma cannot match, it represents the main generic-substitution risk for AGB-Pharma's Rx melatonin.
• H. Lundbeck: Lundbeck is a major Danish CNS-focused pharma with a broader sleep portfolio (including modafinil and other CNS drugs). It is a broad incumbent in European sleep medicine with marketing muscle that dwarfs AGB-Pharma's and the most credible big-pharma threat in the melatonin/sleep space.
• Viatris: Viatris (post-Mylan-Pfizer Upjohn combination) markets a broad Rx portfolio across Europe including generic melatonin and CNS products. As a global low-cost generics and established brands giant, it represents an aspirational competitive ceiling and potential future consolidator in the European pediatric ADHD/sleep market.
• Karo Pharma: Karo Pharma is a Nordic specialty OTC/RX pharma with sleep and pediatric products (formerly part of Karo and now under the STADA Nordic group). Comparable in Nordic heritage, regulatory profile, and focus on sleep/pediatric adjacencies where AGB-Pharma plays.
• Desitin Pharma: Desitin is a privately held German specialty pharma with a focus on neurology and sleep medicine (including Circadin distribution in Germany). Overlap in indications and Nordic/DACH commercial channel makes it a directly comparable European neurology/sleep specialist incumbent.

Others

• Recipharm: Recipharm is a Nordic CDMO that operates EU-GMP facilities capable of producing small-batch Rx tablets. As a Swedish pharma manufacturer neighbour and potential production partner, it is thematically adjacent and tied into the same Nordic supply ecosystem that supports AGB-Pharma.

Emerging players

• Biocodex: Biocodex is a privately held European specialty pharma with neurology, pediatric, and women's health focus, including sleep-adjacent OTC products. Comparable in size and family-owned footing to AGB-Pharma, with similar European footprint and pediatrician-led commercial model.
• Church & Dwight (Natrol): Natrol (a Church & Dwight subsidiary) is the largest US melatonin supplement brand. While OTC/supplement rather than Rx, it shapes consumer awareness of melatonin and is a frequent comparator cited to prescribers and payors when evaluating AGB-Pharma's Rx premium.

Direct peers

• Flynn Pharma: Flynn Pharma holds the UK distribution rights to Circadin (Rx melatonin). AGB-Pharma also distributes in the UK; Flynn is therefore the most direct in-market competitor for the same prescriber audience and same API.
• Neurim Pharmaceuticals: Neurim is the maker of Circadin, the leading prescription prolonged-release melatonin for insomnia. It is the closest direct competitor to AGB-Pharma's Melatonin AGB and Pinealin, operating in the same European Rx melatonin category and targeting similar adult insomnia and adjacent indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/agb-pharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AGB-Pharma